We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

No sugar coating

10 November 2014 By Neil Unmack, Robert Cyran

Obamacare and healthy competition are to blame for Sanofi’s problems in the insulin market. But copycat “biosimilar” drugs will disrupt other pharmaceutical markets. These new-style generics could create big problems for some substantial firms, including Amgen and AbbVie.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)